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Crosstalk between transcription factors and cyto-
kines precisely regulates tissue homeostasis. Tran-
scriptional intermediary factor 1g (TIF1g) regulates
vertebrate hematopoietic development, can control
transcription elongation, and is a component of the
TGF-b signaling pathway. Here we show that dele-
tion of TIF1g in adult hematopoiesis is compatible
with life and long-term maintenance of essential
blood cell lineages. However, loss of TIF1g results
in deficient long-term hematopoietic stem cell (LT-
HSC) transplantation activity, deficient short-term
HSC (ST-HSC) bone marrow retention, and priming
ST-HSCs to myelomonocytic lineage. These defects
are hematopoietic cell-autonomous, and priming of
TIF1g-deficient ST-HSCs can be partially rescued
by wild-type hematopoietic cells. TIF1g can form
complexes with TAL1 or PU.1—two essential DNA-
binding proteins in hematopoiesis—occupy specific
subsets of their DNA binding sites in vivo, and
repress their transcriptional activity. These results
suggest a regulation of adult hematopoiesis through
TIF1g-mediated transcriptional repression of TAL1
and PU.1 target genes.
INTRODUCTION
Adult hematopoiesis is initiated by a population of hematopoietic
stem cells (HSCs) that can differentiate into committed progen-
itors, producing all of the mature specialized hematopoietic cells
(Orkin and Zon, 2008). Bone marrow (BM) HSCs are located in
specialized structures called niches, where they may self-renew,
remain quiescent, undergo apoptosis, or differentiate into
progenitors. These processes depend on a finely tuned balance
of cell-intrinsic (mostly transcription factors) and cell-extrinsic
(adhesion molecules and/or receptor ligands) regulators (Lym-412 Cell Stem Cell 8, 412–425, April 8, 2011 ª2011 Elsevier Inc.peri et al., 2010). As most of the signaling pathways initiated
by these cell-extrinsic regulators ultimately culminate in the
nucleus, crosstalk between cell-intrinsic and inducible transcrip-
tion factors might regulate adult hematopoietic development
(Zon, 2008), and understanding of adult hematopoiesis at the
molecular level will require integration of intrinsic and extrinsic
control of this differentiation.
The importance of transcriptional intermediary factor 1g
(TIF1g; also referred to as ectodermin, TRIM33, RFG7, or
PTC7) in hematopoiesis has come from a genetic study of blood-
less zebrafish mutants called moonshine. These mutants have
premature stop codon mutations in the zebrafish ortholog of
mammalian TIF1g (Ransom et al., 2004) and displayed cell-
autonomous defects in both primitive and definitive adult hema-
topoiesis, resulting in severe anemia (Ransom et al., 2004). TIF1g
is a member of the TIF family of transcriptional coactivators and
corepressors (Venturini et al., 1999; Yan et al., 2004). The four
members of the TIF family contain an amino-terminal RING-
finger B-box coiled-coil (RBCC/TRIM) motif that is involved in
protein-protein interactions (Reymond et al., 2001) and a car-
boxy-terminal bromodomain (Bromo) preceded by a PHD finger,
twomotifs found in proteins that act at the chromatin level. TIF1a
can function as a coactivator for retinoic acid receptors (Zhong
et al., 1999), and TIF1b can function as a corepressor for the
Kru¨ppel-associated box (KRAB) domain zinc-finger transcription
factors and as a cofactor for HP1 protein in heterochromatin-
mediated gene silencing (Abrink et al., 2001). No such function
has been reported for TIF1g, but TIF1g can form hetero-oligo-
mers with TIF1a and TIF1b, suggesting that TIF1g can act as
a transcriptional corepressor or a transcriptional coactivator
(Peng et al., 2002). Indeed, moonshine mutants with TIF1g
proteins that lack the middle region and the carboxy-terminal
Bromo and PHD domains have severe anemia, indicating an
important role of TIF1g at the chromatin level (Ransom et al.,
2004).
In contrast with the well-defined phenotype of the moonshine
mutants (Ransom et al., 2004), the role of TIF1g in adult hemato-
poiesis has only been studied in the erythroid differentiation of
TIF1g-deficient primary human hematopoietic progenitors using
shRNA downregulation strategy (He et al., 2006; Bai et al., 2010),
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hematopoiesis remain controversial. TIF1g is a newly identified
component of the TGF-b signaling that acts either through selec-
tive binding to receptor-phosphorylated Smad2/3 complex in
competition with Smad4 (He et al., 2006) and/or through mono-
ubiquitination of nuclear Smad4 preventing Smad4 nuclear
localization (Dupont et al., 2005, 2009; Morsut et al., 2010).
Functionally, TIF1g/receptor-phosphorylated Smad2/3 interac-
tion results in erythroid differentiation in response to TGF-bwhile
Smad4/receptor-phosphorylated Smad2/3 interaction results in
TGF-b antiproliferative response of erythroid cells. TIF1g also
controls erythroid cell fate through regulation of transcription
elongation of specific genes that might be targets of the blood-
specific TAL1 transcription complex (Bai et al., 2010), indicating
that TAL1 can provide a cell-specific regulation of both transcrip-
tion initiation and elongation during erythroid cell differentiation.
Although phenotypes of moonshine and TGF-b pathway-defi-
cient animals are different, the TGF-b pathway might contribute
to the TIF1g-dependent elongation, and thus, TIF1g might be
a link between cell-extrinsic and cell-intrinsic regulation of
hematopoiesis.
As TIF1g null mice are embryonic-lethal at day 9.5 with
a dramatic developmental delay (Kim and Kaartinen, 2008), we
use a conditional mouse strain that allows for the deletion of
TIF1g in the hematopoietic system. We show that deletion of
TIF1g leads to numerous hematopoietic defects, including inac-
curate HSC long-term reconstitution capacity, commitment, and
BM retention, and suggests that these TIF1g functions might be
related to TIF1g-mediated inhibition of TAL1 and PU.1 transcrip-
tional activity. These results pinpoint TIF1g as an important regu-
lator of transcription during adult hematopoiesis.
RESULTS
TIF1gRegulatesMultiple Stages of Adult Hematopoiesis
TIF1g mRNA was detected in all of the hematopoietic popula-
tions, but TIF1g mRNA levels were higher in KLS CD34 cells
and common myeloid progenitors (CMPs) and erythroid and
B-lymphoid lineages (Figure S1A available online). Along with
previous studies (Bai et al., 2010; He et al., 2006; Ransom
et al., 2004), this expression pattern suggested a role for TIF1g
in hematopoiesis and prompted us to study the effects of
TIF1g gene deletion on hematopoiesis. As germline TIF1g gene
deletion is embryonic-lethal (Kim and Kaartinen, 2008), we
conditionally inactivated TIF1g by breeding a TIF1gfl/fl strain
with interferon-inducible Mx-Cre transgenic animals (Kuhn
et al., 1995) and treatment with poly(I)-poly(C) (pIpC) every day
for 7 days (Figure 1A). Genomic PCR and western blotting of
control (Mx-Cre/TIF1gWT/WT, pIpC injected, referred to as WT/
WT) and TIF1g-deficient (Mx-Cre/TIF1gfl/fl, pIpC injected,
referred to as D/D) mice confirmed TIF1g gene deletion in the
BMand lineage-negative (Lin) hematopoietic cells (Figure S1B).
Two months after pIpC injection, peripheral blood (PB) analysis
revealed similar counts of PB leukocytes (data not shown)
and no abnormalities in circulating red blood cells, but fewer
B-lymphocytes and more granulocytes/monocytes in D/D mice
(Figure 1B). BM analyses 2 and 7 months after pIpC treatment
revealed that the loss of TIF1g did not change the total
BM cellularity (data not shown), but resulted in alterationsin the erythroid, B-lymphoid, and myeloid compartments, with
decreased numbers of Ter119hiCD71+ and B220+ cells (Fig-
ure 1C, left panels; Figures S1C and S1D, left panels) and an
increased number of Gr1+CD11b+ cells (data not shown). The
decreased number of Ter119hiCD71+ cells in the BM was
balanced by increased erythropoiesis in the spleen (Figure 1C,
right panels; Figure S1C, right panel), and D/D mice did not
have any anemia. TIF1g deficiency resulted in an altered early
B-lymphoid differentiation illustrated by an increased number
of pre-pro-B cells (AA4.1+, IL7Ra+, B220med, c-Kit+) associated
with decreased numbers of pro-B (AA4.1+, IL7Ra+, B220med,
c-Kit) and pre-B (AA4.1+, IL7Ra+, B220hi, c-Kit) cells (Fig-
ure 1D; Figure S1D, right panel) and an increased number of
apoptotic pre-B cells (data not shown) in D/D mice. These
changes in mature hematopoietic cells were associated with
an increased number of granulocyte-monocyte progenitors
(GMPs) (2.3-fold), a profound decrease in the number of CMPs
and megakaryocyte-erythrocyte progenitors (MEPs) (14- and
5.3-fold, respectively), and no change in the number of common
lymphoid progenitors (CLPs) (Figure 1E; Figure S1E, left panel).
According to the surface markers used for phenotyping
(Challen et al., 2009), TIF1g gene deletion resulted in a 9-
to 2.5-fold decrease in the number of long-termHSCs (LT-HSCs;
KLS flk2CD34 and KLS CD150+CD48 cells, respectively),
a 1.4-fold increase in the number of short-term HSCs (ST-HSCs;
KLS flk2CD34+), and a 5.5-fold increase in the number of multi-
potent progenitors (MPPs; KLS flk2+CD34+) (Figure 1E; Fig-
ure S1E, middle and right panels). To construe how fewer LT-
HSCs can give rise tomore ST-HSCs, the cell-cycle distributions
of these cells were studied. No significant difference in cell-cycle
distribution was observed between TIF1g-deficient and control
KLS flk2CD34 cells (Figure 1F, top panel), but the percentage
of quiescent TIF1g-deficient ST-HSCs in G0 decreased 2-fold,
with a correlative increase in the percentage of cycling S-G2/M
cells (Figure 1F, left bottompanel; Figure S1F, left panel). Bromo-
deoxyuridine (BrdU) incorporation revealed increased prolifera-
tion rates of TIF1g-deficient ST-HSCs in vivo, with a 2-fold
increase in the number of BrdU+ ST-HSCs, whereas similar
BrdU uptakes were observed in TIF1g-deficient versus control
MPPs (Figure 1F, right panel; Figure S1F, right panel). Together,
these results indicate a role for TIF1g in many stages of adult
hematopoiesis.
TIF1g Deletion Results in Deficient HSC Self-Renewal
and Defects in Niche Retention
Because Mx-Cre can induce the deletion in both hematopoietic
cells and BM microenvironment (Walkley et al., 2007), we
assessed the intrinsic contribution of TIF1g in HSCs and progen-
itors using a transplantation strategy. Whole BM from Mx-Cre/
TIF1gWT/WT or Mx-Cre/TIF1gfl/fl mice (both CD45.2+) was trans-
planted into lethally irradiated recipient mice (CD45.1+), and all
of the mice were treated with pIpC 4 weeks after transplantation
(Figure 2A). Loss of TIF1g in hematopoietic cells (TIF1gD/D cells)
did not change BM cellularity 1, 2, or 4 months after pIpC treat-
ment (Figure S2A), but resulted in alterations in TIF1gD/D progen-
itors and HSCs similar to those observed inD/Dmice (Figure 2B),
indicating that this phenotype is hematopoietic cell-autono-
mous. Donor CD45.2+ TIF1gD/D or TIF1gWT/WT BM cells were
then isolated and transplanted into lethally irradiated CD45.1+Cell Stem Cell 8, 412–425, April 8, 2011 ª2011 Elsevier Inc. 413
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similar engraftment and BM cellularity were observed (Fig-
ure S2B). Analysis of BM hematopoietic progenitors of these
recipients 2 months after transplantation revealed a 5.3-fold
decrease in the number of CMPs, a 6.7-fold decrease in the
number of MEPs, a 4.5-fold increase in the number of GMPs,
a similar number of KLS cells, and a 4.8-fold decrease in the
number of KLS CD34 cells when TIF1gD/DBMwas transplanted
(Figure 2C; Figure S2C). Donor CD45.2+ BM cells from these
transplanted mice were isolated and injected into secondary
recipients (Figure 2A). While all of themice receivingWTBMcells
survived, 80% of the mice receiving TIF1g-deficient BM died
from aplasia 60 days after the secondary transplantation (Fig-
ure 2D). These results indicate that TIF1g is necessary for
optimal HSC function in transplantation assays.
To evaluate how loss of TIF1g affects HSC engraftment, we
assessed the homing and niche retention of TIF1gD/D KLS cells.
Homing was monitored after intravenous injection of 5,000
CFSE-labeled TIF1gWT/WT or TIF1gD/D KLS cells into lethally
irradiated mice. Similar numbers of CFSE-labeled cells were
detected 24 hr after TIF1gWT/WT or TIF1gD/D KLS cell transplan-
tation (data not shown). Interestingly, the TIF1gD/D KLS cells
rapidly divided, and 72 hr after transplantation, 2-fold fewer cells
with a 2-fold reduced fluorescence mean were detected in the
femurs of the mice transplanted with TIF1gD/D KLS cells (Fig-
ure 2E). These results suggest that initial homing is not depen-
dent on TIF1g expression in KLS cells and strengthen the cycling
of TIF1gD/D KLS cells. Twomonths after pIpC treatment, analysis
of circulating TIF1gD/D or TIF1gWT/WT KLS cells showed a 20-fold
increase in the number of TIF1gD/DKLS cells in the PB (Figure 2F,
left panel). Furthermore, AMD3100 treatment did not result in
increased mobilization of the BM TIF1gD/D KLS cells, whereas
it mobilized BM TIF1gWT/WT KLS cells (Figure 2F, right panel).
These results indicate that the retention within BM niches (rather
than homing to the niche) contributes, in part, to the observed
defect of TIF1gD/D HSC engraftment.
Cell-Intrinsic and Non-Cell-Intrinsic Defects
of TIF1g-Deficient Hematopoietic Cells
To determine the in vitro hematopoietic potential of TIF1g-defi-
cient ST-HSCs cells, we used long-term culture-initiating cell
(LTC-IC) and colony-forming cell (CFC) assays. The loss of
TIF1g in purified ST-HSCs caused a 2-fold decrease in the
number of LTC-ICs (Figure 3A, left panel) and a 1.7-fold decreaseFigure 1. TIF1g Regulates Numerous Stages of Adult Hematopoiesis
(A) Schematic of experimental design.
(B) PB phenotype in WT/WT and D/D mice, 2 months after pIpC treatment. Bloo
Percentage of B220+, CD3+, and Gr1+CD11b+ cells (right). Same results were ob
(C) Representative FACS analyses of Ter119medCD71+ and Ter119hiCD71+ eryth
mice 2 months after pIpC treatment (n = 4).
(D) Representative FACS analyses of pre-pro-B cells (AA4.1+, IL7Ra+, B220med,
IL7Ra+, B220hi, c-Kit) from BM of WT/WT and D/D mice, 2 months after pIpC tr
(E) Representative FACS analyses of MEPs (Lin, Sca-1, c-Kit+, CD16/32, C
c-Kit+, CD16/32+, CD34+), KLS flk2 CD34 cells (Lin, Sca-1+, c-Kit+, flk2, CD3
flk2+, CD34+), and KLS CD150+CD48 cells (Lin, Sca-1+, c-Kit+, CD150+, CD4
treatment (n = 10).
(F) Live Hoechst (H) and Pyronin Y (PY) staining of LT-HSCs and ST-HSCs. Repre
(H > 2n-4n/PY+) LT-HSCs (top panel) and ST-HSCs (left bottom panel) (n = 5). FAC
See also Figure S1.inmyeloid CFC activity (Figure 3A,middle panel). The numbers of
all the colony types were decreased proportionally (Figure 3A,
middle panel), and the sizes and morphologies of WT and
TIF1g-deficient ST-HSCs were similar (Figure S3A). Secondary
cultures revealed a 5.5-fold decrease in the number of TIF1gD/D
colonies (Figure 3A, right panel), indicating the diminished self-
renewal of TIF1g-deficient myeloid progenitors.
Next, we evaluated the functional capacities of TIF1gD/D
hematopoietic cells in a competitive repopulation assay. Whole
CD45.2+ BM fromTIF1gWT/WT or TIF1gD/Dmicewas transplanted
at a 1:1 or a 5:1 ratio with CD45.1+ WT competitor BM into
lethally irradiatedmice (Figure 3B). These two ratioswere chosen
to surround the decreased number of TIF1gD/D KLS CD150+
CD48 cells that were highly enriched in LT-HSCs (2.5-fold).
Four months after transplantation, loss of TIF1g did not change
the total BM cellularity (data not shown). Competitive transplan-
tation at a 1:1 ratio with TIF1gWT/WT cells achieved 60%
chimerism in the experimental donor compared with less than
2% obtained with TIF1gD/D cells 4 months after transplantation
(Figure 3C). Competitive transplantation at a 5:1 ratio with
TIF1gD/D cells achieved 40.7% chimerism in the experimental
donor compared with 84.5% obtained with TIF1gWT/WT cells
and 20% chimerism in the Lin BM population compared with
78% obtained with TIF1gWT/WT cells (Figure 3C). Analysis of
CD45.2+ HSCs in the 5:1 ratio transplantation assay exhibited
a 3-fold decrease in the percentage of KLS CD34 cells
and a 1.5-fold increase in the percentage of KLS cells when
TIF1gD/D BM cells were used (Figure 3D, left panel). These differ-
ences agree with the results obtained in noncompetitive trans-
plantation assays. A 3.6-fold increase in the percentage of
GMPs was found in TIF1gD/D CD45.2+ cells compared to
TIF1gWT/WT CD45.2+ cells, but no difference was found in the
percentage of CMPs and MEPs when TIF1gD/D and TIF1gWT/WT
CD45.2+ cells were compared (Figure 3D, middle and left
panels), indicating a partial rescue of TIF1g-deficient CMPs
and MEPs by WT competitor hematopoietic cells. To rule out
any possible competition in engraftment between TIF1gWT/WT
and TIF1gD/D hematopoietic cells, whole BM from Mx-Cre/
TIF1gWT/WT or Mx-Cre/TIF1gfl/fl was transplanted at a 1:1 ratio
with WT competitor BM into lethally irradiated recipient mice
and treated with pIpC 4weeks after transplantation (Figure S3B).
Identical alterations in chimerism were observed 2 and 4months
after pIpC treatment (data not shown), and analyses of the
different progenitor compartments revealed intrinsic defects ind count (left). RBC, red blood cell; MCV, mean cell volume; Hb, hemoglobin.
tained at 7 months post-treatment. Mean ± SEM, n = 5.
roblast subsets from bone marrow (left) and spleen (right) of WT/WT and D/D
c-Kit+), pro-B cells (AA4.1+, IL7Ra+, B220med, c-Kit) and pre-B cells (AA4.1+,
eatment (n = 6).
D34), CMPs (Lin, Sca-1, c-Kit+, CD16/32lo, CD34+), GMPs (Lin, Sca-1,
4), ST-HSCs (Lin, Sca-1+, c-Kit+, flk2, CD34+), MPPs (Lin, Sca-1+, c-Kit+,
8/CD244) from BM of WT/WT (left) and D/D mice (right) 7 months after pIpC
sentative FACS analysis of quiescent G0 (H
2n, PY), G1 (H
2n, PY+), and S-G2/M
S analysis of BrdU+ ST-HSCs and MPPs (right bottom panel) (n = 5).
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Figure 2. TIF1g Deletion Results in Hematopoietic Cell-Autonomous Defects, Decreased HSC Capacity in Transplantation Assays, and
Altered KLS Niche Retention
(A) Schematic of experimental design.
(B) Percentage of the different immature hematopoietic lineages in the CD45.2+ BMpopulations of TIF1gWT/WT and TIF1gD/Dmice, 4months after pIpC treatment.
Mean ± SEM, n = 5–20 mice per genotype.
(C) Representative FACS analysis of myeloprogenitors (top: gated as Lin, Sca-1, c-Kit+, and analysis for CD16/32 and CD34 expressions) and HSCs (bottom:
gated as Lin, Sca-1+, c-Kit+, and analysis for CD34 expression) fromBMof lethally irradiated recipients, 2months post-transplantation with CD45.2+ TIF1gWT/WT
or TIF1gD/D BM cells (n = 6 TIF1gWT/WT, n = 5 TIF1gD/D).
(D) Kaplan-Meier survival plot of secondary recipient after lethal irradiation and transplantation with CD45.2+ TIF1gWT/WT or TIF1gD/D BM cells (left). Total number
of cells in BM from secondary recipients 40 days after transplantation (right). Mean ± SEM, n = 6.
(E) Total number (left) or fluorescence mean (right) of CFSE-labeled cells detected in femurs of lethally irradiated mice, 72 hr post-transplantation with 5,000
CFSE-labeled TIF1gWT/WT or TIF1gD/D KLS cells. Mean ± SEM, n = 3.
(F) Representative FACS analysis of TIF1gWT/WT and TIF1gD/D KLS cells in PB 2 months after pIpC treatment. PB cells were gated as Lin and analyzed for c-Kit
and Sca-1 expression (left) (n = 3). Fold increase of TIF1gWT/WT and TIF1gD/DKLS cells in PB, 1 hr after injection of AMD3100 into pIpC-treatedmice (right). Mean ±
SEM, n = 3.
See also Figure S2.
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Figure 3. Cell-Intrinsic and Non-Cell-Intrinsic Defects of TIF1g-Deficient Hematopoietic Cells
(A) LTC-IC potential of sorted TIF1gWT/WT and TIF1gD/D ST-HSCs. Different numbers of cells were cocultured into individual MS5-coated 96-well plates for
4 weeks and then plated in methylcellulose medium. Myeloid CFC activity was scored after 7 days of culture and the percentage of wells containing no colonies
was plotted against the initial number of seeded cells (12 wells/cell number seeded) (left). TIF1gWT/WT and TIF1gD/D ST-HSCs (100) were cultured in methyl-
cellulose medium. The bar graph shows the number of mixed (Mix), granulocyte-macrophage (CFC-GM), macrophage (CFC-M), granulocyte (CFC-G), and
erythroid (E) colonies scored after 7 days of culture (middle). Mean ± SEM of triplicate cultures. Number of colonies obtained after secondary CFC plating in
methylcellulose medium (right). Mean ± SEM, n = 3.
(B) Schematic of experimental design.
(C) Chimerism of total (left) and Lin (right) cells in the BM of mice 4months after lethal irradiation and transplantation with 106 or 5.106 TIF1gWT/WT or TIF1gD/DBM
cells together with 106 competitor WT BM cells. Mean ± SEM, n = 3.
(D) Percentage of KLS CD34 and KLS cells (left) and myeloprogenitors (right) in CD45.2+ BM population of mice 4 months after lethal irradiation and trans-
plantation with 5.106 TIF1gWT/WT or TIF1gD/D BM cells together with 106 competitor WT BM cells. Mean ± SEM, n = 3. Representative FACS analyses of Tif1gD/D
myeloprogenitors in the presence (upper middle panel) or absence (lower middle panel) of WT competitor BM cells.
(E) Chimerism of total BM 2months after lethal irradiation and secondary transplantation of unfractionated BM cells from mice previously transplanted with a 5:1
ratio of CD45.2+:CD45.1+ cells. Mean ± SEM, n = 3.
See also Figure S3.
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chimerism was similar for CMPs and MEPs, strengthening the
notion that WT competitor hematopoietic cells can partially
rescue TIF1g-deficient CMPs and MEPs. Finally, the decreased
chimerism of the TIF1gD/D KLS CD34 cells found in the 5:1 ratio
was further monitored by a secondary transplantation (Fig-
ure 3B). Two months after this secondary transplantation, PB
(data not shown) and BM chimerisms revealed that TIF1gD/D
HSCs are unable to engraft secondary recipients in the presence
of WT BM cells (Figure 3E). Thus, competitor BM was unable to
rescue the TIF1gD/D HSC defects but could partially rescue the
impaired commitment of TIF1gD/D MPPs into CMPs and the
differentiation of CMPs into MEPs, indicating that normal hema-topoietic cells can respond to some of the defects caused by
TIF1g deletion.
Widespread Transcriptional Deregulation
in TIF1g-Deficient ST-HSCs and Progenitors
To characterize the molecular mechanisms underlying the bio-
logical properties of TIF1gD/D KLS cells, we performed global
gene expression analysis and compared the gene expression
profiles of TIF1gD/D and TIF1gWT/WT KLS cells purified 4 months
after pIpC treatment (GEO accession number GSE22280). This
analysis revealed broad transcriptional deregulations in TIF1g-
deficient KLS cells and prompted us to analyze the expression
levels of known hematopoietic regulators in TIF1g-deficientCell Stem Cell 8, 412–425, April 8, 2011 ª2011 Elsevier Inc. 417
Figure 4. Altered Gene Expression of TIF1g-Deficient ST-HSCs and Progenitors
(A) Quantitative RT-PCR analysis of the indicated genes in sorted ST-HSCs and MPPs from BM of TIF1gWT/WT and TIF1gD/D mice. Data are the average fold
changes relative to TIF1gWT/WT cells ± SD, n = 3. GAPDH mRNA levels were used as an internal reference.
(B) Representative FACS analysis of CD16/32 surface expression of TIF1gWT/WT and TIF1gD/D KLS CD34+ cells (n = 20).
(C) Sorted TIF1gWT/WT and TIF1gD/D ST-HSCs were cocultured with MS5 or MS5DL1 cells with or without 5 ng/ml of TGF-b1. After 4 days of culture, cells were
counted (left) and 1,000 cells were plated in methylcellulose medium. Number of colonies was scored at day 7 of culture (right). Mean ± SEM, n = 3.
(D) Representative FACS analysis of TIF1gWT/WT and TIF1gD/D ST-HSCs (top) and MPPs (bottom) analyzed for CXCR4 staining (left). Bar graph represents the
percentage of input of TIF1gWT/WT or TIF1gD/D ST-HSCs that migrated in the presence of SDF-1 (right). Mean ± SEM, n = 3.
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RT-PCR (Figures 4A and 4E; Figures S4A and S4D). In TIF1g-
deficient ST-HSCs, increased mRNA levels of genes that
regulate self-renewal (Pten, Pbx1, and c-myc) or cell cycle
(cyclin D1, p21, and p27) along with decreased expression
of c-mpl, cyclin D2, and p57 could be observed (Figure 4A)
and might be related to the enhanced proliferation of TIF1g-defi-
cient ST-HSCs. Of the known transcriptional regulators of hema-
topoiesis, we found an increased expression of genes that
promote myeloid differentiation (Gata2, PU.1, Egr1, or Id1)
and a decreased expression of genes that impair myeloid differ-
entiation (Id2, Eklf, or Fli1) or antagonized the functions of PU.1
(SpiB or SpiC) in TIF1g-deficient ST-HSCs or MPPs (Figure 4A).
In MPPs, PU.1 and Gfi1 have opposite roles, promoting myeloid
versus lymphoid specification (Spooner et al., 2009). PU.1 and
Gfi1 mRNA levels were both increased in TIF1gD/D MPPs (Fig-
ure 4A), indicating why a normal number of CLPs was found
in TIF1gD/D BM despite an increased PU.1 mRNA level. The
increased PU.1 mRNA level in MPPs was also associated
with decreased Gata1 mRNA levels, indicating why TIF1gD/D
MPPs exhibited higher myelo/lymphoid potential. Finally, we
observed increased levels of CD32 (FcgR2b) in TIF1gD/D
ST-HSCs and MPPs (Figure 4A), which are associated with
high expression of the CD16/32 protein in most of TIF1g-defi-
cient KLS CD34+ cells, whereas most of WT KLS CD34+ cells
expressed medium-to-low levels of CD16/32 (Figure 4B; Fig-
ure S4B). The increased expression of CD16/32 is associated
with the differentiation of CMPs toward GMPs, and thus,
TIF1g-deficient KLS CD34+ cells harbor a GMP-like phenotype
that contrasts withWTKLSCD34+ cells. All these results suggest
a potential priming of TIF1g-deficient KLS CD34+ cells toward
GMPs.
The expression levels of genes involved in the Notch (Notch1
and Hes1), TGF-b (TGFbRI, TGFbRII, and Smad4) and the Igf
(Igf1) pathways were decreased (except for Hes1) in TIF1g-defi-
cient ST-HSCs (Figure 4A), indicating that TIF1g-deficient ST-
HSCs might have altered sensitivities to extracellular signals.
To document this sensitivity, TIF1gWT/WT and TIF1gD/D ST-
HSCs were cultured for 4 days on control MS5 cells or on MS5
stromal cells expressing the Notch ligand Delta-1 (MS5DL1) in
the absence or presence of TGF-b1. This in vitro system mimics
part of the BM niche (Santaguida et al., 2009). We then assayed
the myeloid CFC activities and quantified the numbers of
myeloid progenitors generated under each coculture condition.
Stimulation with TGF-b1 and/or activation of the Notch pathway
impaired the growth of TIF1gD/D and TIF1gWT/WT ST-HSCs in
a similar manner (Figure 4C, left panel). Cultured TIF1gD/D ST-
HSCs exhibited a 2-fold decrease in myeloid CFC activity after
growth on MS5±TGF-b1 and a 10-fold increase in myeloid
CFC activity after growth on MS5DL1+TGF-b1 (Figure 4C, right
panel), indicating an altered response to TGF-b1/Notch signaling
in TIF1g-deficient ST-HSCs. Finally, we studied the mRNA levels
of genes involved in BM retention or homing and found
decreased expression levels of C1q, Ccl6, and CXCR4 in(E) Quantitative RT-PCR analysis of the indicated genes in sorted CMPs, GMPs, a
and shown as in (A).
See also Figure S4.TIF1g-deficient ST-HSCs and MPPs (Figure 4A). The decreased
CXCR4mRNA level in TIF1g-deficient ST-HSCs was associated
with decreased expression of CXCR4 protein at the ST-HSC and
MPP cell surfaces (Figure 4D, left panel; Figure S4C) and with
impaired migration of TIF1g-deficient ST-HSCs in the presence
of the CXCR4 ligand SDF-1 (Figure 4D, right panel). In contrast
with the large variations in mRNA levels found in ST-HSCs and
MPPs, only mild variations of genes encoding regulators of
hematopoiesis were found in TIF1gD/D CMPs, GMPs, and
MEPs (Figure 4E; Figure S4D), strengthening the role of TIF1g
in ST-HSCs and MPPs.
TIF1g Can Interact with TAL1 and PU.1, Occupy TAL1
and PU.1 Regulatory Sequences In Vivo, and Repress
TAL1 and PU.1 Transcriptional Activity on Specific
Genes
A striking feature of the BM from TIF1gD/D hematopoietic cells is
the cell-intrinsic decrease in the number of LT-HSCs and
increase in the size of the GMP population. TAL1 is a key player
in the transition of the LT-HSCs into ST-HSCs (Lacombe et al.,
2010), and PU.1 plays important roles in GMP versus MEP
segregation (Dakic et al., 2005). Therefore, we searched for
any possible interaction between TIF1g and either TAL1 or
PU.1. We found that TIF1g can coimmunoprecipitate with
TAL1 or PU.1 in Lin BM, MEL erythroid, and 32D myeloid cells
(Figure 5A). The TIF1g/TAL1 complex has been recently
described (Bai et al., 2010) and is associated with the transcrip-
tion elongation of erythroid genes (such as Gata1 or Tal1). Using
Gata1 (resp. Tal1)-specific primers near the 50 or 30 ends, we
found similar levels of Gata1 (resp. Tal1) transcripts in all purified
hematopoietic populations studied, indicating that TIF1g might
not act on the PolII elongation of Gata1 or Tal1 genes in mouse
adult hematopoiesis (Figure S5A). Thus, we determined whether
any TIF1g/TAL1 or TIF1g/PU.1 associations were present on the
regulatory sequences of known TAL1 or PU.1 target genes using
chromatin immunoprecipitation (ChIP) analysis. Three known
TAL1 target genes (Gata1, Gata2, and Id1) and three known
PU.1 target genes (p15INK4b, egr2, and FcgR2b) were studied
(Figure 5B). TIF1g could bind to a subset of TAL1 regulatory
sequences, as shown by its binding to the +9.5kb but not
the 2.8kb regulatory sequences of the Gata2 gene (Figure 5B,
upper panels). TIF1g also exhibited cell-specific binding to PU.1
regulatory sequences, as shown by the absence of TIF1g
binding to the FcgR2b gene promoter bound by PU.1 in MEL
cells (Figure 5B, lower panels).
Transient transfection of HEK293 or HeLa cells with vectors
encoding Flag-tagged TIF1g and either HA-tagged TAL1 or
myc-tagged PU.1 followed by immunoprecipitations showed
that Flag-tagged TIF1g could form complexes with TAL1 and
PU.1 (Figure 5C). TIF1g is a member of a family of transcriptional
repressors (Venturini et al., 1999), and the TAL1/TIF1g and PU.1/
TIF1g associations suggest the existence of TIF1g-mediated
repression of TAL1 or PU.1 transcriptional activity. In transient
assays using a reporter gene driven by the GpA promoter (LahlilndMEPs from BM of TIF1gWT/WT and TIF1gD/Dmice (n = 3). Data were analyzed
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Figure 5. TIF1g Can Interact with and Regulate TAL1 and PU.1 Transcriptional Activity
(A) Coimmunoprecipitation of TIF1g and TAL1 (top) and TIF1g and PU.1 (bottom) in LinBMcells and in erythroid (MEL) andmyeloid (32D) cell lines. Total extracts
were immunoprecipitated with anti-TIF1g antibody or anti-mouse IgG (IgGM) and the precipitated proteins were revealed by immunoblotting using the indicated
antibodies. The signal obtained with 5% of input is shown.
(B) ChIP analyses of TIF1g, TAL1, and PU.1 occupancy of the indicated loci in chromatin purified from LinBMcells, MEL, and 32D cell lines. Immunoprecipitated
DNA was quantified by quantitative RT-PCR using region-specific primers. Positions relative to the transcriptional start site are indicated. Data represent the
enrichment ± SD over the IgG signal, normalized to a negative control region in the GAPDH gene (n = 3).
(C) HEK293 cells were transiently transfectedwith Flag-TIF1g and HA-TAL1 vectors, or with an empty vector as a control (left). HeLa cells were cotransfectedwith
plasmids encoding Flag-TIF1g and myc-PU.1 (right). Immunoprecipitations were performed using an anti-Flag antibody, and the precipitated proteins were
revealed by immunoblotting using the indicated antibodies. The signal obtained with 1% of input is shown.
(D) Luciferase reporter assay in HEK293 cells transfected with a GpA reporter plasmid, the TAL1 complex (TAL1, E2A, GATA1, Ldb1, and LMO2), and increasing
amounts of Flag-TIF1g expression vector (left). Control experiments were performed in the absence of the TAL1 complex or the GpA promoter. Luciferase
reporter assay in HeLa cells transfected with a c-fes-TK-luc reporter construct (fes) or a mutant c-fes-TK-luc reporter construct (mutant fes), a myc-PU.1
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responsive elements of the c-fes gene promoter), there was
a 20-fold (versus a 30-fold) activation of the GpA promoter
(versus the PU.1-responsive promoter) by the TAL1 activating
complex (versus PU.1), and TIF1g repressed this activity in
a dose-dependent manner (Figure 5D, left panel for the GpA
promoter, and right panel for the PU.1-responsive promoter).
TIF1g can bind to some of the regulatory regions of the Gata1,
Gata2, p15INK4b, and egr2 genes (Figure 5B) and modulate
their mRNA levels in hematopoietic cells (Figure 4E). Thus, we
determine the effects of TIF1g overexpression on the expression
of these four genes in MEL and 32D cells and the chromatin
structure of some of their regulatory regions. The binding of the
overexpressed TIF1g to the previously identified TAL1 or PU.1
binding sites of the Gata1, Gata2, p15INK4b, and egr2 genes
was associated with decreases in their mRNA levels (Figures
5E and 5F), indicating that TIF1g can repress these target genes.
Finally, the recruitment of overexpressed TIF1g onto the
p15INK4b and egr2 promoters was associated with a switch
from activating (H3K14ac) to repressive (H3K9me3) histone
marks on these two promoters, indicating the existence of
a TIF1g-dependent chromatin structure for these two gene
promoters (Figure 5F, right panel). These TIF1g-dependent
histone marks cannot be generalized because TIF1g overex-
pression does not modify the histone marks on the Gata2 gene
promoter and the +9.5 kb regulatory sequence of the Gata2
gene (Figure S5C).DISCUSSION
TIF1gwas identified in zebrafish as a permissive cofactor for the
erythrocyte lineage-specific control of hematopoietic gene
expression (Ransom et al., 2004) and, using in vitro cell culture,
as a factor regulating human erythropoiesis (Bai et al., 2010;
He et al., 2006). Using a conditional mouse strain allowing for
deletion of TIF1g in the hematopoietic system, we showed that
mice can live without any expression of TIF1g in hematopoietic
cells and are not anemic—results that contrast with the effects
of TIF1g deletion in zebrafish. However, analyses of TIF1g-defi-
cient hematopoiesis showed a role of TIF1g in many stages of
hematopoiesis. TIF1g deletion affected hematopoietic stem
cells, CMP/MEP/GMP compartments, and B-lymphoid,
myeloid, and erythrocytic lineages in a cell-autonomousmanner.
In addition, we extended themolecular functions of TIF1g, which
is described as a regulator of the TGF-b signaling pathway
(Dupont et al., 2005; He et al., 2006) and transcriptional elonga-
tion (Bai et al., 2010), to the transcriptional repression of a subsetexpression vector, and increasing amounts of Flag-TIF1g (right). The TK-renilla r
n = 3.
(E) (left) Quantitative RT-PCR analysis of Gata1 and Gata2mRNA levels and ChIP
Flag antibody in MEL cells expressing or not expressing Flag-TIF1g. GAPDH
immunoprecipitated DNA was quantified by quantitative RT-PCR using region-s
compared with a negative control region (GAPDH0.2kb). (right) Quantitative RT-
in (left). Mean ± SD, n = 3.
(F) Quantitative RT-PCR analysis of p15 and egr2mRNA levels in 32D cells either
and egr2 promoters with an anti-Flag antibody (left) and with anti-H3K14ac and an
over IgG ± SD, n = 3. The GAPDH gene promoter was used as a control.
See also Figure S5.of PU.1 and TAL1 target genes through the direct association
with these two essential regulators of adult hematopoiesis.TIF1g and the Hematopoietic Stem Cell Compartment
Whereas TIF1g-deficient LT-HSCs were able to sustain hemato-
poiesis in adults, TIF1g-deficient LT-HSCs had an impaired
capacity to reconstitute hematopoiesis after secondary trans-
plantation. These results indicate that TIF1g is not absolutely
required for LT-HSC self-renewal but may regulate the long-
term maintenance of adult LT-HSCs after transplantation. TAL1
protein has a similar function in adult hematopoiesis (Lacombe
et al., 2010), and the TIF1g/TAL1 association (Bai et al., 2010,
and see below) might indicate that a new pathway regulates
the long-term maintenance of adult LT-HSCs. In the next hema-
topoietic compartment, we found a higher number of ST-HSCs
and MPPs in TIF1g-deficient mice, despite a 2.5-fold decrease
in the number of KLS CD150+/CD48 cells that were highly
enriched in LT-HSCs. This could be explained by the increased
proliferation capacity of TIF1g-deficient ST-HSCs, which may
be associated with direct or indirect changes in their cell cycle
regulators (increased cyclin D1, p21, and p27 CKI mRNA levels
and decreased cyclin D2 and p57 CKI mRNA levels). Concomi-
tantly, the mRNA levels of c-mpl (the thrombopoietin [TPO]
receptor) were dramatically decreased in TIF1g-deficient ST-
HSCs. TPO released from the stem cell niche activates the
c-mpl expressed in HSCs and is important for the maintenance
of HSC quiescence (Yoshihara et al., 2007). Thus, the decreased
c-mplmRNA levels might be linked to the proliferation of TIF1g-
deficient ST-HSCs. Analysis of mRNAs expressed in TIF1g-defi-
cient ST-HSCs and MPPs revealed decreased mRNA levels of
CXCR4, an essential homing/retention receptor, and members
of the complement cleavage fragments (C1q) that have been
shown to enhance the homing/retention of hematopoietic
stem/progenitor cells in BM by priming/enhancing the chemo-
tactic response of HSCs to a low SDF1 gradient (Jalili et al.,
2010). The impaired BM retention of TIF1g-deficient ST-HSCs
might be associated with these decreased mRNA and, for
CXCR4, surface protein levels. Non-competitive transplanta-
tions have shown that a WT niche environment cannot rescue
the phenotype of TIF1g-deficient BM, and we showed that the
Notch and TGF-b signaling pathways are altered in TIF1g-defi-
cient HSCs. Controversial results have been published regarding
the role of these two pathways in LT-HSCmaintenance and self-
renewal in vivo (Larsson et al., 2003; Maillard et al., 2008), but
both regulate the production of myeloid progenitors from the
HSCs (Challen et al., 2010). TIF1g might directly or indirectly
regulate the effectors of these pathways, including the Hes1eporter vector was used for normalization under both conditions. Mean ± SD,
analyses of Gata1 and Gata2 genes indicated regulatory regions with an anti-
mRNA levels were used as a control for quantitative RT-PCR analyses and
pecific primers. The values are presented as the fold enrichment over IgG and
PCR and ChIP analyses were performed in 32D cells in the same conditions as
expressing or not expressing Flag-TIF1g as in (E) (left). ChIP analysis of the p15
ti-H3K9me3 antibodies (right). The values are presented as the fold enrichment
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TIF1g-deficient HSCs exhibited numerous alterations that
resulted in impaired HSC capacity in transplantation assays.
TIF1g and Myelomonocytic Commitment
We also found a function of TIF1g in the restriction of early hema-
topoietic progenitor commitment toward the myeloid lineage, as
early TIF1g-deficient progenitors were primed to enter the mye-
lomonocytic lineage at the expense of the erythrocytic lineage.
The hierarchical model of hematopoiesis suggests that the lack
of CMPs will result in diminished numbers of GMPs and MEPs.
In TIF1g-deficient BM, the decreased CMP population was
associated with increased levels ofPU.1mRNA inMPPs, a larger
number of GMPs, and a smaller number of MEPs. This pheno-
type is the reverse of the phenotype of PU.1-deficient adult
BM, in which the lack of CMPs was associated with an absence
of GMPs and a larger number of MEPs (Iwasaki et al., 2005).
Furthermore, the premature expression of CD16/32 in TIF1g-
deficient KLS CD34+ cells suggests that, in these mutant mice,
KLS CD34+ cells might be directly primed to become GMPs
without the CMP step. Although the increased expression of
CD16/32 could be explained by TIF1g directly repressing the
CD16 and/or CD32 gene(s), the increased number of MPPs
expressing the CD16/32 antigen and the gene expression
observed in TIF1g-deficient MPPs suggests that these MPPs
may have acquired aGMP-like phenotype. Recently, a computa-
tional model indicated that the PU.1/Gata1 cross-antagonism
that happens in MPPs was insufficient to explain the erythroid-
myeloid switch and predicted the existence of a PU.1 repressor
that is potentially activated by Gata1 (Chickarmane et al., 2009).
TIF1g shares many properties with this cofactor as it represses
PU.1 gene expression (directly or indirectly) and can repress
PU.1 transcriptional activity through an association with PU.1.
Whether TIF1g is a Gata1 target gene remains to be determined,
but the presence of GATA-binding sites in the TIF1g gene
promoter suggests such regulation. Finally, competitive BM
transplantations demonstrated a partial rescue of TIF1g-defi-
cient CMPs andMEPs, but not HSCs or B-lymphoid populations,
and a cell-intrinsic increase in myelomonocytic differentiation.
These results indicate that the signals generated by WT BM
competitor hematopoietic cellsmight be used by TIF1g-deficient
hematopoietic progenitors to produce CMPs and MEPs. Thus,
the balance of positive and negative signals that commit progen-
itors to become CMPs, MEPs, or GMPs is partially non-cell-
intrinsic. Whether the signals are directly produced by BM
hematopoietic cells themselves or by the BM microenvironment
in the presence of BM competitor hematopoietic cells remains to
be determined.
TIF1g and Transcriptional Activity in Hematopoietic
Cells
In contrast to TIF1a and TIF1b, which act as transcriptional
cofactors, themolecular function of TIF1g remains controversial.
The role of TIF1g in the TGF-b signaling pathway has been docu-
mented during development and in adults, but its molecular
function in this pathway has not been definitively determined.
TIF1g acts either on Smad2/3 or Smad4, depending on the
studies (Dupont et al., 2005; He et al., 2006). Recently, genetic
and biochemical evidence have shown that TIF1g can regulate422 Cell Stem Cell 8, 412–425, April 8, 2011 ª2011 Elsevier Inc.transcription elongation, widening the molecular functions of
TIF1g in hematopoietic cells. In this study, we showed that
TIF1g could form complexes with two essential hematopoietic
transcription factors (TAL1 and PU.1) and inhibits their transcrip-
tional activities. Furthermore, we demonstrated that TIF1g could
bind to the regulatory sequences occupied by TAL1 on regula-
tors of hematopoiesis, such as the Gata1,Gata2, and Id1 genes.
TIF1g can also bind to the regulatory sequences occupied by
PU.1 on the p15, egr2, and FcgR2b genes. We also found
a correlation between TIF1g expression and the mRNA levels
of these genes.
Previous studies have demonstrated that TAL1 is essential for
erythropoiesis (Hall et al., 2003; Mikkola et al., 2003), mainte-
nance of quiescence, long-term competence of HSCs (Brunet
de la Grange et al., 2006; Lacombe et al., 2010), and proliferation
and differentiation of monocyte precursors (Brunet de la Grange
et al., 2008; Dey et al., 2010). TIF1g gene deletion results in
defects in these three hematopoietic populations, suggesting
a connection between the phenotype observed in the TIF1g-
deficient hematopoietic cells and the TIF1g/TAL1 association.
The binding of TIF1g to the +9.5kb TAL1-binding sequence
(Dey et al., 2010; Wozniak et al., 2007), but not to the 2.8kb
TAL1-binding sequence of the GATA2 gene (Tripic et al.,
2009), indicates that TIF1g might be associated with TAL1 on
a subset of TAL1-binding sites. This alternating association of
TAL1 with repressors or activators has already been described
for the ETO2/TAL1 interaction (Fujiwara et al., 2009; Goardon
et al., 2006), and local fluctuations in the association of TAL1
with activators or repressors would account for the graded
expression of specific genes during hematopoietic differentia-
tion. TIF1g is required to counteract PolII pausing factors by
recruiting elongation factors to erythroid genes by interacting
with the TAL1 complex, which can regulate both transcription
initiation and elongation. The association of TIF1g to TAL1-
binding sites indicates that looping mechanisms might be
involved in the recruitment of TIF1g by the PolII transcription
complex.
PU.1 is an essential factor for maintenance of normal HSC
function, the lineage commitment of hematopoietic progenitors,
and the terminal differentiation of myeloid cells into macro-
phages (Burda et al., 2010). Although PU.1 can associate with
numerous general and specific transcription factors that modu-
late PU.1-dependent hematopoietic cell-fate decisions, we
speculate a connection between the phenotype observed in
TIF1g-deficient hematopoietic cells and the TIF1g/PU.1 associ-
ation. Overexpression of TIF1g in the myeloid 32D cell line
resulted in the binding of the overexpressed TIF1g protein to
PU.1 binding sites in the gene promoters of the CDK inhibitor
p15INK4b and egr2 and was associated with decreased mRNA
levels of these two genes and changes in the histone marks of
these two promoters. These results suggested a function for
TIF1g in the transcriptional regulation of PU.1 target genes.
TIF1g may be a new component of the PU.1-nucleated com-
plexes that are formed at the regulatory sites of PU.1 target
genes and regulate the transcription levels of these genes.
In conclusion, we have provided genetic evidence that TIF1g
contributes to optimal function of HSCs and to their commitment
and differentiation into hematopoietic lineages. We also found
that TIF1g can associate with and regulate the transcriptional
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TAL1 and PU.1. Understanding how TIF1g regulates the tran-
scriptional activity of TAL1 and PU.1 at the molecular level and
the potential link between these regulations and the hematopoi-
etic phenotype of TIF1g-deficient mice will offer insights into
stem cell self-renewal and differentiation.
EXPERIMENTAL PROCEDURES
Mice
Congenic C57BL/6-CD45.1 mice (10- to 12-weeks old) were used as donors
for purification of WT cells and as recipients for transplantation experiments.
TIF1gfl/fl C57BL/6-CD45.2 mice (R. Losson) were crossed with Mx-Cre C57/
BL6-CD45.2 mice (Kuhn et al., 1995). Cre expression was induced by seven
consecutive daily intraperitoneal (IP) injections of pIpC in 8-week-old mice.
Mice were maintained in a specific pathogen-free animal facility (registration
number: A920322) and handled in compliance with the institutional guidelines
and French Ministry of Agriculture’s regulations.
Flow Cytometry
Cell preparation, staining for flow-cytometry analysis, and cell sorting are
detailed in the Supplemental Experimental Procedures.
Transplantation, Homing, and Mobilization Assays
Congenic recipient mice were lethally irradiated and transplanted with 106
unfractionated BM cells from Mx-Cre/TIF1gWT/WT or Mx-Cre/TIF1gfl/fl mice
via retro-orbital injection under methoxyflurane anesthesia 24 hr after irradia-
tion. Recipient mice were treated with pIpC 4 weeks postengraftment. For
serial transplantations, 106 unfractioned CD45.2+ TIF1gWT/WT or CD45.2+
TIF1gD/D BM cells were used. For competition transplantations, 106 or 5.106
unfractioned CD45.2+ TIF1gWT/WT or CD45.2+ TIF1gD/D BM cells were trans-
planted together with 106 CD45.1+ WT competitor BM cells.
For homing experiments, 5000 sorted TIF1gWT/WT or TIF1gD/D KLS cells
were stained at a final concentration of 0.5 mM of CFSE (Invitrogen) and trans-
planted into lethally irradiated mice. Flow-cytometry analyses were performed
24 and 72 hr later. For mobilization experiments, TIF1gWT/WT and TIF1gD/D
mice were IP injected with AMD3100 (5 mg/kg). PB cells were harvested
1 hr post-AMD3100 injection and analyzed by flow cytometry.
Cell Proliferation Assays
Lin cells from BM of WT/WT and D/Dmice were first incubated with Hoechst
33342 and Pyronin Y and then labeled with surface markers. For BrdU assay,
WT/WT and D/Dmice were IP injected with BrdU (1 mg) 24 hr before sacrifice.
BM cells were stained with surface markers prior to BrdU detection with
a BrdU labeling kit, as described by the manufacturer (BD).
BM Cocultures, LTC-IC, CFC, and Migration Assays
Cocultures were performed in StemSpan serum-free medium (StemCell
Technologies) supplemented with 100 ng/ml of mouse IL11 (R&D Systems),
100 ng/ml of mouse Flt-3 ligand (Miltenyi Biotec), 50 ng/ml of mouse SCF
(StemCell Technologies), and 5 ng/ml of LDL solution (Sigma). Sorted ST-
HSCs (1,000) from TIF1gWT/WT or TIF1gD/D mice were seeded on monolayers
of MS5 and MS5DL1 cells plated in a 96-well plate (5,000 cells per well) the
day before and grown for up to 4 days with or without 5 ng/ml of TGF-b1
(R&D Systems). Following the culture period, HSC-derived cells were
collected, counted on a hematocymeter, and replated in Methocult M3434
(StemCell Technologies). Colony numbers were evaluated 7 days after plating.
For LTC-IC assays, varying cell doses of sorted ST-HSCs (150 to 5 cells/12
wells per dose) from TIF1gWT/WT or TIF1gD/Dmice were seeded in monolayers
of MS5 cells plated in a 96-well plate (5000 cells per well) the day before and
cultured in a MyeloCult M5300 medium supplemented with 106 M hydrocor-
tisone (StemCell Technologies) at 33C for 4 weeks with weekly replacements
of one-half of the medium. At the end of the culture period, the adherent and
non-adherent cells were harvested from each individual well and assayed in
methylcellulose cultures for CFCs. Colonies were scored at day 7 and the
proportion of negative wells (no CFCs detected) was calculated for each cell
dose used.For CFC assays, sorted ST-HSCs (100) from TIF1gWT/WT or TIF1gD/D mice
were plated in triplicate in Methocult M3434 (StemCell Technologies). Colony
numbers andmorphologies were evaluated 7 days after culture. Colonieswere
then replated at 10,000 cells per dish.
For migration assays, transwell chambers (Costar) were used to assess cell
migration through filters (pore size 6.5 mm). Sorted ST-HSCs (10,000) from
TIF1gWT/WT or TIF1gD/D mice were seeded in the upper chamber in RPMI
medium and 0.6 ml of medium containing 100 ng/ml of SDF-1 were added
to the bottom chamber. After 4 hr of incubation at 37C, cells in the bottom
of the chamber were stained with Hoechst 33342 and the cell number was
quantified by flow cytometry using the TruCount method (BD).
Quantitative RT-PCR
Total RNA of FACS-sorted cell populations from either TIF1gWT/WT or TIF1gD/D
mice was isolated using an RNeasy Micro kit (QIAGEN) and amplified (Messa-
geAmpII kit, Ambion). PCR reactions were prepared as described previously
(Kusy et al., 2010), and primer sequences are available upon request.
Cell Lines Transfections, Reporter Assay, Immunoblotting Analysis,
and ChIP
Experiments were performed using procedures detailed in the Supplemental
Experimental Procedures.
Statistics
Quantitative data are expressed as the Mean ± SEM or the Mean ± SD.
Statistical significance was assayed using a nonparametric Mann Whitney
test. *p < 0.05.
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